Functional evidence of des-Arg10-kallidin enzymatic inactivating pathway in isolated human umbilical vein
- PMID: 17372720
- DOI: 10.1007/s00210-007-0145-y
Functional evidence of des-Arg10-kallidin enzymatic inactivating pathway in isolated human umbilical vein
Abstract
It has been known for many years that plasma and tissues contain a variety of enzymes capable of metabolizing kinins. The aim of the present study was to evaluate, by means of functional studies in a capacitance vessel such as the human umbilical vein (HUV), the possible role played by the metallopeptidases angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP), and aminopeptidase M (APM) as an inactivating pathway of the B(1) receptor endogenous agonist des-Arg(10)-kallidin (DAKD). In HUV rings with and without endothelium, concentration-response curves (CRCs) to DAKD were determined after a 300-min incubation period, and enzymatic inhibitors were added to the organ baths 30 min before construction of the CRC. Presence of endothelial layer was confirmed by histological studies. There was a significant leftward shift observed in control HUV rings devoid of endothelium compared with intact tissues. Exposure to 1 microM captopril (ACE inhibitor) potentiated DAKD-elicited vasoconstrictor responses in HUV rings with endothelium while no such effect was observed in tissues devoid of endothelium. Application of 10 microM amastatin (APM inhibitor) induced a leftward shift of DAKD-elicited contractile responses in HUV with and without endothelium. On the other hand, 10 microM phosphoramidon (NEP inhibitor) showed no potentiating effect in HUV rings either with or without endothelium. However, under concurrent inhibition of ACE, NEP and APM, there was a higher potentiation of DAKD-elicited contractile responses compared with the effect observed with combined inhibition of ACE and APM. Moreover, when we evaluated contractile responses induced by Sar(0)-D-Phe(8)-des-Arg(9)-BK (a metabolically protected B(1) receptor agonist), no potentiating effect was observed under triple enzymatic inhibition. In conclusion, in the present study for the first time, we demonstrated in a capacitance vessel, HUV, that metallopeptidases ACE, NEP and APM represent a relevant functional inactivation pathway of DAKD.
Similar articles
-
Potentiation of des-Arg9-kallidin-induced vasoconstrictor responses by metallopeptidase inhibition in isolated human umbilical artery.J Pharmacol Exp Ther. 2005 Jun;313(3):1355-60. doi: 10.1124/jpet.105.083063. Epub 2005 Mar 11. J Pharmacol Exp Ther. 2005. PMID: 15764737
-
Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: an effective bradykinin inactivation pathway.Eur J Pharmacol. 2011 Sep 30;667(1-3):271-7. doi: 10.1016/j.ejphar.2011.05.045. Epub 2011 Jun 1. Eur J Pharmacol. 2011. PMID: 21651905
-
Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase.Circulation. 1999 Apr 20;99(15):1984-90. doi: 10.1161/01.cir.99.15.1984. Circulation. 1999. PMID: 10209002
-
Vasopeptidase inhibition: a double-edged sword?Hypertension. 2003 Mar;41(3):383-9. doi: 10.1161/01.HYP.0000054215.71691.16. Epub 2003 Feb 3. Hypertension. 2003. PMID: 12623931 Review.
-
Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.Kidney Int Suppl. 2003 May;(84):S54-7. doi: 10.1046/j.1523-1755.63.s84.35.x. Kidney Int Suppl. 2003. PMID: 12694309 Review.
Cited by
-
A Robust Bioassay of the Human Bradykinin B2 Receptor that Extends Molecular and Cellular Studies: The Isolated Umbilical Vein.Pharmaceuticals (Basel). 2021 Feb 24;14(3):177. doi: 10.3390/ph14030177. Pharmaceuticals (Basel). 2021. PMID: 33668382 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous